The intra-tumoral administration of cyclic dinucleotide-based STING agonists improves the therapeutic outcomes of glioma in both mouse and dog models, a result of enhanced type-I IFN, CXCL10 and CCL5 signaling and T cell infiltration into the brain and conversion of the glioma-associated immunosuppressive TME to an immunogenic TME [60,61]. This evidence concerns the gene STING1 and central nervous system cancer.